{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:08:46Z","timestamp":1791446926123,"version":"4.3.3"},"reference-count":22,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":4106,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Diabetes and heart failure commonly coexist, and prior studies have suggested better outcomes with metformin than other antidiabetic agents. We designed this study to determine whether this association reflects a beneficial effect of metformin or a harmful effect of other agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We performed a case-control study nested within the U.K. General Practice Research Database cohort in which diagnoses were assigned by each patient's primary care physician. Case subjects were patients 35 years or older, newly diagnosed with both heart failure and diabetes after January 1988, and who died prior to October 2007. Control subjects were matched to case subjects based on age, sex, clinic site, calendar year, and duration of follow-up. Analyses were adjusted for comorbidities, A1C, renal function, and BMI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The duration of concurrent diabetes and heart failure was 2.8 years (SD 2.6) in our 1,633 case subjects and 1,633 control subjects (mean age 78 years, 53% male). Compared with patients who were not exposed to antidiabetic drugs, the current use of metformin monotherapy (adjusted odds ratio 0.65 [0.48\u20130.87]) or metformin with or without other agents (0.72 [0.59\u20130.90]) was associated with lower mortality; however, use of other antidiabetic drugs or insulin was not associated with all-cause mortality. Conversely, the use of ACE inhibitors\/angiotensin receptor blockers (0.55 [0.45\u20130.68]) and \u03b2-blockers (0.76 [0.61\u20130.95]) were associated with reduced mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Our results confirm the benefits of trial-proven anti-failure therapies in patients with diabetes and support the use of metformin-based strategies to lower glucose.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc09-2227","type":"journal-article","created":{"date-parts":[[2010,3,19]],"date-time":"2010-03-19T00:46:55Z","timestamp":1268959615000},"page":"1213-1218","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":111,"title":["Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case\u2013Control Study From the U.K. General Practice Research Database"],"prefix":"10.2337","volume":"33","author":[{"given":"Michael R.","family":"MacDonald","sequence":"first","affiliation":[{"name":"Golden Jubilee National Hospital, Glasgow, Scotland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean T.","family":"Eurich","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Alberta, Edmonton, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit R.","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, University of Alberta, Edmonton, Alberta, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewsey","sequence":"additional","affiliation":[{"name":"Department of Public Health and Health Policy, University of Glasgow, Glasgow, Scotland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Bhagra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sunderland Royal Hospital, Sunderland, England;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"Department of Public Health and Health Policy, University of Glasgow, Glasgow, Scotland;"},{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital, Glasgow, Scotland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finlay A.","family":"McAlister","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, University of Alberta, Edmonton, Alberta, Canada;"},{"name":"Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031218230567800_B1","doi-asserted-by":"crossref","first-page":"113B","DOI":"10.1016\/j.amjcard.2006.11.013","article-title":"Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy","volume":"99","author":"Masoudi","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022031218230567800_B2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2006.10.077","article-title":"A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure","volume":"49","author":"Dargie","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022031218230567800_B3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.39314.620174.80","article-title":"Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review","volume":"335","author":"Eurich","year":"2007","journal-title":"BMJ"},{"key":"2022031218230567800_B4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cardfail.2009.10.022","article-title":"Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes","volume":"16","author":"Shah","year":"2010","journal-title":"J Card Fail"},{"key":"2022031218230567800_B5","first-page":"337","article-title":"The UK General Practice Research Database","volume-title":"Pharmacoepidemiology","author":"Gelfand","year":"2005","edition":"4th ed"},{"key":"2022031218230567800_B6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-5-5","article-title":"Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure","volume":"5","author":"Essebag","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2022031218230567800_B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/diacare.28.1.20","article-title":"Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting","volume":"28","author":"Maru","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031218230567800_B8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(04)16765-2","article-title":"Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey","volume":"364","author":"Hippisley-Cox","year":"2004","journal-title":"Lancet"},{"key":"2022031218230567800_B9","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"2022031218230567800_B10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2005.02.093","article-title":"Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure","volume":"46","author":"Doehner","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2022031218230567800_B11","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/euhj.1999.2043","article-title":"Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure","volume":"21","author":"Suskin","year":"2000","journal-title":"Eur Heart J"},{"key":"2022031218230567800_B12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.numecd.2008.09.002","article-title":"Insulin resistance in chronic heart failure: a difficult bull to take by the horns","volume":"19","author":"Sacc\u00e0","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2022031218230567800_B13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacc.2007.10.021","article-title":"Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options","volume":"51","author":"Witteles","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022031218230567800_B14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"The hemoglobin A1C level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch Intern Med"},{"key":"2022031218230567800_B15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2005.10.008","article-title":"An unexpected inverse relationship between HbA1C levels and mortality in patients with diabetes and advanced systolic heart failure","volume":"151","author":"Eshaghian","year":"2006","journal-title":"Am Heart J"},{"key":"2022031218230567800_B16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2009.04.049","article-title":"Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes","volume":"54","author":"Aguilar","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2022031218230567800_B17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.7326\/0003-4819-150-11-200906020-00008","article-title":"Glycemic control in type 2 diabetes: time for an evidence-based about-face?","volume":"150","author":"Montori","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031218230567800_B18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022031218230567800_B19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0002-8703(03)00403-4","article-title":"Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials","volume":"146","author":"Haas","year":"2003","journal-title":"Am Heart J"},{"key":"2022031218230567800_B20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.7326\/0003-4819-138-11-200306030-00016","article-title":"Applying evidence to patient care: from black and white to shades of grey","volume":"138","author":"McAlister","year":"2003","journal-title":"Ann Intern Med"},{"issue":"6","key":"2022031218230567800_B21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"issue":"19","key":"2022031218230567800_B22","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","article-title":"Cardiovascular outcomes in trials of oral diabetes medications: a systematic review","volume":"168","author":"Selvin","year":"2008","journal-title":"Arch Intern Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/33\/6\/1213\/605461\/zdc00610001213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/33\/6\/1213\/605461\/zdc00610001213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:23:57Z","timestamp":1647113037000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/33\/6\/1213\/27136\/Treatment-of-Type-2-Diabetes-and-Outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,1]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc09-2227","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,1]]}}}